4+ day, 22+ hour ago   (230+ words) The Pharma Letter - Kura launches new company, diabetes focused Caspian Therapeutics US biotech Kura Oncology (Nasdaq: KURA) today announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian…...

3+ week, 2+ day ago   (588+ words) The Pharma Letter A clinical-stage biopharmaceutical company focused on WEE1 inhibition in biomarker-selected ovarian cancer, with its lead asset azenosertib approaching a pivotal registration-enabling data readout in 2026. Zentalis Pharmaceuticals discovers and develops small molecule therapeutics targeting fundamental biological pathways in cancer....

3+ week, 4+ day ago   (243+ words) The Pharma Letter - Kynexis raises 97 million euros to advance med for cognitive disorders Dutch clinical-stage biotech Kynexis today announced the closing of a 40 million euros ($46.3 million) Series A extension bringing total Series A financing to 97 million euros ($110 million). The financing…...

3+ week, 5+ day ago   (275+ words) The Pharma Letter - Dash Bio banks $30 million to automate development bottleneck USA-based bioanalysis firm Dash Bio has raised $30 million in a series A round led by Oak HC/FT, money it will spend on a laboratory that hands much of…...

3+ week, 5+ day ago   (212+ words) thepharmaletter.com - OmniAb signs $370 million ion channel discovery deal with Eli Lilly California-based antibody discovery technology provider OmniAb (Nasdaq: OABI) has entered a global collaboration and license agreement with US pharma major Eli Lilly (NYSE: LLY) covering a new ion…...